Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Table 1 Univariate and multivariate analysis of risk factors for bRFS and DMFS

	Risk factor	Reference category	Univariate analysis			Multivariate analysis
			HR	95% CI	p	HR	95% CI	p
bRFS
	T-stage	T3b-T4			0.047			0.112
	T1b-T2a		0.64	0.43–0.94	0.025	0.653	0.44–0.98	0.038
	T2b-T2c		0.60	0.39–0.91	0.016	0.672	0.43–1.04	0.075
	T3a		0.76	0.53–1.09	0.134	0.91	0.63–1.30	0.608
	PSA		1.01	1.01–1.02	<.0005	1.015	1.01–1.02	<0.0005
	Gleason score	GS > 7			0.148			<0.0005
	< 7		0.68	0.46–1.00	0.053	0.349	0.23–0.53	<0.0005
	= 7		0.83	0.58–1.19	0.307	0.604	0.41–0.89	0.010
	ADT duration (continuous)		0.97	0.96–0.99	0.001	0.979	0.96–1.00	0.017
	Radiation dose		0.83	0.77–0.89	<0.0005	0.859	0.79–0.93	<0.0005
DMFS
	T-stage	T3b-T4			0.204			0.272
	T1b-T2a		0.62	0.37–1.02	0.061	0.634	0.38–1.06	0.081
	T2b-T2c		0.65	0.38–1.11	0.117	0.695	0.40–1.22	0.204
	T3a		0.84	0.54–1.29	0.424	0.916	0.59–1.42	0.694
	PSA		1.01	1.00–1.02	0.004	1.009	1.00–1.01	0.011
	Gleason score	GS > 7			0.137			0.013
	< 7		0.61	0.37–0.99	0.047	0.482	0.29–0.79	0.004
	= 7		0.77	0.49–1.21	0.254	0.730	0.46–1.17	0.189
	ADT duration (continuous)		0.99	0.97–1.01	0.366
	Radiation dose		0.86	0.78–0.95	0.004	0.853	0.77–0.95	0.003

Abbreviations: bRFS biochemical relapse-free survival, CI confidence interval, DMFS distant metastases-free survival

ISSN: 1471-2490